/MRNS

MRNS Stock - Marinus Pharmaceuticals, Inc.

Q: What is the analyst price target for MRNS?

Analyst price target information is not currently available for MRNS.

Q: What is MRNS's market cap?

Market capitalization information is not currently available for MRNS.

Healthcare|Biotechnology|NASDAQ

$0.55+0.00%

+$0.00 (+0.00%) • Feb 10

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+809.1%upside

Target: $5.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for MRNS

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

FY2023

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.26

52W High$10.50

52W Low$0.22

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2023	FY2022	FY2021	FY2020	FY2019
Revenue	$30.99M	$25.48M	$15.35M	$1.72M	N/A
Gross Profit	$29.05M	$25.14M	$13.87M	$-48,788,000	$-503,000
Gross Margin	93.8%	98.7%	90.4%	-2839.8%	N/A
Operating Income	$-131,485,000	$-112,788,000	$-96,931,000	$-67,937,000	$-54,422,000
Net Income	$-141,405,000	$-19,816,000	$-101,660,000	$-66,642,000	$-53,767,000
Net Margin	-456.3%	-77.8%	-662.5%	-3879.0%	N/A
EPS	$-2.63	$-0.51	$-2.77	$-2.44	$-3.95

Company Overview

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

50%

Hold / Neutral

50%

Sell / Underperform

Analyst Consensus🟡 Mixed

2 Bullish2 Neutral/Bearish

Price Targets

Average Target

↑ 1463.6% Upside

Now

Low

Average

$23

High

Based on 5 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
September 23rd 2024	Oppenheimer	Upgrade	Outperform	$6
August 14th 2024	Ladenburg Thalmann	Downgrade	Neutral	-
April 16th 2024	Robert W. Baird	Downgrade	Neutral	$2← $20
April 15th 2024	RBC Capital Mkts	Downgrade	Sector Perform	$3← $24
August 11th 2023	Oppenheimer	Downgrade	Perform	$9← $14
January 20th 2023	RBC Capital Mkts	Initiation	Outperform	$23

Earnings History & Surprises

MRNS

Beat Rate

53%

Last 17 quarters

Avg Surprise

-20.6%

EPS vs Estimate

Beats / Misses

9/7

1 met exactly

Latest EPS

$-0.74

Q1 2025

EPS Surprise History

Q2 23

+13.0%

$-0.67vs$-0.77

Q3 23

+19.7%

$-0.61vs$-0.76

Q4 23

+9.0%

$-0.61vs$-0.67

Q1 24

-15.6%

$-0.74vs$-0.64

Q2 24

0.0%

$-0.68vs$-0.68

Q3 24

-1.7%

$-0.60vs$-0.59

Q4 24

+4.5%

$-0.42vs$-0.44

Q1 25

-155.2%

$-0.74vs$-0.29

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2025	Nov 10, 2025	—	—	—	—
Q3 2025	Aug 11, 2025	—	—	—	—
Q2 2025	May 6, 2025	—	—	—	—
Q1 2025	Mar 4, 2025	$-0.29	$-0.74	-155.2%	✗ MISS
Q4 2024	Nov 12, 2024	$-0.44	$-0.42	+4.5%	✓ BEAT
Q3 2024	Aug 13, 2024	$-0.59	$-0.60	-1.7%	✗ MISS
Q2 2024	May 8, 2024	$-0.68	$-0.68	0.0%	= MET
Q1 2024	Mar 5, 2024	$-0.64	$-0.74	-15.6%	✗ MISS
Q4 2023	Nov 7, 2023	$-0.67	$-0.61	+9.0%	✓ BEAT
Q3 2023	Aug 10, 2023	$-0.76	$-0.61	+19.7%	✓ BEAT
Q2 2023	May 11, 2023	$-0.77	$-0.67	+13.0%	✓ BEAT
Q1 2023	Mar 7, 2023	$-0.91	$-0.76	+16.5%	✓ BEAT
Q4 2022	Nov 7, 2022	$0.25	$-0.35	-240.0%	✗ MISS
Q3 2022	Aug 11, 2022	$-0.93	$-1.06	-14.0%	✗ MISS
Q2 2022	May 12, 2022	$-0.87	$-0.52	+40.2%	✓ BEAT
Q1 2022	Mar 21, 2022	$-0.81	$-0.77	+4.9%	✓ BEAT
Q4 2021	Nov 9, 2021	$-0.76	$-0.53	+30.3%	✓ BEAT
Q3 2021	Aug 10, 2021	$-0.68	$-0.65	+4.4%	✓ BEAT
Q2 2021	May 17, 2021	$-0.46	$-0.74	-60.9%	✗ MISS
Q1 2021	Mar 9, 2021	$-0.52	$-0.55	-5.8%	✗ MISS

Frequently Asked Questions about MRNS

What is MRNS's current stock price?

Marinus Pharmaceuticals, Inc. (MRNS) is currently trading at $0.55 per share. The stock has moved +0.00% today.

What is the analyst price target for MRNS?

The average analyst price target for MRNS is $5.00, based on 1 analyst.

What sector is Marinus Pharmaceuticals, Inc. in?

Marinus Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is MRNS's market cap?

Marinus Pharmaceuticals, Inc. has a market capitalization of $0.03 billion, making it a small-cap company.

Does MRNS pay dividends?

No, Marinus Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.